Literature DB >> 30637797

A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components.

Marta Bofill Roig1, Guadalupe Gómez Melis1.   

Abstract

Composite binary endpoints are increasingly used as primary endpoints in clinical trials. When designing a trial, it is crucial to determine the appropriate sample size for testing the statistical differences between treatment groups for the primary endpoint. As shown in this work, when using a composite binary endpoint to size a trial, one needs to specify the event rates and the effect sizes of the composite components as well as the correlation between them. In practice, the marginal parameters of the components can be obtained from previous studies or pilot trials; however, the correlation is often not previously reported and thus usually unknown. We first show that the sample size for composite binary endpoints is strongly dependent on the correlation and, second, that slight deviations in the prior information on the marginal parameters may result in underpowered trials for achieving the study objectives at a pre-specified significance level. We propose a general strategy for calculating the required sample size when the correlation is not specified and accounting for uncertainty in the marginal parameter values. We present the web platform CompARE to characterize composite endpoints and to calculate the sample size just as we propose in this paper. We evaluate the performance of the proposal with a simulation study and illustrate it by means of a real case study using CompARE.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  composite binary endpoints; correlated endpoints; sample size

Year:  2019        PMID: 30637797     DOI: 10.1002/sim.8092

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  1 in total

1.  Sample size estimation using a latent variable model for mixed outcome co-primary, multiple primary and composite endpoints.

Authors:  Martina E McMenamin; Jessica K Barrett; Anna Berglind; James M S Wason
Journal:  Stat Med       Date:  2022-02-23       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.